The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of E2609 when administered as single doses to healthy adult volunteers and healthy elderly subjects. The study will consist of 2 parts:(1) a single dose in healthy adult volunteers, at doses up to 800 mg or the maximum dose that can be tolerated, (2) a single dose of 50 mg in healthy elderly volunteers.
The study will consist of 2 parts: (1) a single dose in healthy adult volunteers, at doses up to 100 mg or the maximum dose that can be tolerated, (2) a single dose of 25 mg or lower in healthy elderly volunteers.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
73
E2609 orally at varying ascending doses
Matching Placebo
Glendale Adventist Medical Center
Glendale, California, United States
Safety and tolerability as evidenced by the number of subjects with adverse events
Time frame: 38 days
To assess the pharmacokinetics (PK) of E2609 in plasma and urine following administration of single oral doses
Time frame: 4 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.